Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoviCompare-Janssen: COVID-19 Vaccine Immunogenicity in Older Adults
NCT05037266Phase 4Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: IgG humoral response to vaccine at Day 29. Started Sep 2021; status: terminated.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05037266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037266.